Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00262-007-0441-x, but it redirected us to https://link.springer.com/article/10.1007/s00262-007-0441-x. The analysis below is for the second page.

Title[redir]:
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients | Cancer Immunology, Immunotherapy
Description:
Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 ± 0.31% vs. 0.32 ± 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 ± 0.30% vs. 0.27 ± 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 ± 0.23% vs. 0.53 ± 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure how the site profits.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, google, scholar, pubmed, cas, article, cells, dendritic, cell, endothelial, patients, growth, factor, vascular, immature, blood, carbone, immunol, myeloid, gabrilovich, res, human, vegf, plasminogen, maturation, differentiation, access, nadaf, privacy, cookies, function, content, lyerly, morse, immune, immunity, activator, peripheral, breast, vivo, data, publish, research, search, immunotherapy, antivegf, timothy, defective, antitumor, pai,

Topics {✒️}

vegf-mediated tumour angiogenesis month download article/chapter circulating d-dimer levels anti-vegf antibody cd40 ligand-induced maturation urokinase-type plasminogen activators related subjects immature myeloid cell dendritic cell induction immature dendritic cells dendritic cell differentiation full article pdf article cancer immunology immature myeloid cells molecules d-dimer nuclear factor-kappa immature progenitor cells circulating human cd34 immunotherapy article privacy choices/manage cookies research triangle park human tumors inhibits tumor-bearing hosts anti-vegf therapy myeloid suppressor cells impaired anticancer immunity hematopoietic progenitor cells defective antitumor immunity anticancer immune responses urokinase plasminogen activator tumour cells plasminogen activator inhibitor functional endothelial precursors antitumor immune responses plasminogen activator system plasminogen activator inhibitors vivo tumor vascularization della cuna gr metastatic colorectal carcinoma human breast cancer european economic area rationally designed vaccine flow cytometric expertise article osada gabrilovich di human lung tumors defective antigen presentation decreased antigen presentation cancer immunotherapy conditions privacy policy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
         description:Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 ± 0.31% vs. 0.32 ± 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 ± 0.30% vs. 0.27 ± 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 ± 0.23% vs. 0.53 ± 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.
         datePublished:2008-01-10T00:00:00Z
         dateModified:2008-01-10T00:00:00Z
         pageStart:1115
         pageEnd:1124
         sameAs:https://doi.org/10.1007/s00262-007-0441-x
         keywords:
            Dendritic cell
            Immature myeloid cell
            VEGF
            Cancer
            Immunity
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig6_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:57
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Takuya Osada
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gabriel Chong
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert Tansik
               affiliation:
                     name:GlaxoSmithKline
                     address:
                        name:GlaxoSmithKline, Research Triangle Park, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Timothy Hong
               affiliation:
                     name:Hartford Hospital
                     address:
                        name:Hartford Hospital, Hartford, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Neil Spector
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rakesh Kumar
               affiliation:
                     name:GlaxoSmithKline
                     address:
                        name:GlaxoSmithKline, Research Triangle Park, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Herbert I. Hurwitz
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Inderjit Dev
               affiliation:
                     name:GlaxoSmithKline
                     address:
                        name:GlaxoSmithKline, Research Triangle Park, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrew B. Nixon
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. Kim Lyerly
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Timothy Clay
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael A. Morse
               affiliation:
                     name:Duke University Medical Center
                     address:
                        name:Duke University Medical Center, Durham, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
      description:Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 ± 0.31% vs. 0.32 ± 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 ± 0.30% vs. 0.27 ± 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 ± 0.23% vs. 0.53 ± 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.
      datePublished:2008-01-10T00:00:00Z
      dateModified:2008-01-10T00:00:00Z
      pageStart:1115
      pageEnd:1124
      sameAs:https://doi.org/10.1007/s00262-007-0441-x
      keywords:
         Dendritic cell
         Immature myeloid cell
         VEGF
         Cancer
         Immunity
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-007-0441-x/MediaObjects/262_2007_441_Fig6_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:57
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Takuya Osada
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gabriel Chong
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert Tansik
            affiliation:
                  name:GlaxoSmithKline
                  address:
                     name:GlaxoSmithKline, Research Triangle Park, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Timothy Hong
            affiliation:
                  name:Hartford Hospital
                  address:
                     name:Hartford Hospital, Hartford, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Neil Spector
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rakesh Kumar
            affiliation:
                  name:GlaxoSmithKline
                  address:
                     name:GlaxoSmithKline, Research Triangle Park, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Herbert I. Hurwitz
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Inderjit Dev
            affiliation:
                  name:GlaxoSmithKline
                  address:
                     name:GlaxoSmithKline, Research Triangle Park, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrew B. Nixon
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. Kim Lyerly
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Timothy Clay
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael A. Morse
            affiliation:
                  name:Duke University Medical Center
                  address:
                     name:Duke University Medical Center, Durham, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:57
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:GlaxoSmithKline
      address:
         name:GlaxoSmithKline, Research Triangle Park, USA
         type:PostalAddress
      name:Hartford Hospital
      address:
         name:Hartford Hospital, Hartford, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:GlaxoSmithKline
      address:
         name:GlaxoSmithKline, Research Triangle Park, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:GlaxoSmithKline
      address:
         name:GlaxoSmithKline, Research Triangle Park, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
      name:Duke University Medical Center
      address:
         name:Duke University Medical Center, Durham, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Takuya Osada
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:Gabriel Chong
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:Robert Tansik
      affiliation:
            name:GlaxoSmithKline
            address:
               name:GlaxoSmithKline, Research Triangle Park, USA
               type:PostalAddress
            type:Organization
      name:Timothy Hong
      affiliation:
            name:Hartford Hospital
            address:
               name:Hartford Hospital, Hartford, USA
               type:PostalAddress
            type:Organization
      name:Neil Spector
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:Rakesh Kumar
      affiliation:
            name:GlaxoSmithKline
            address:
               name:GlaxoSmithKline, Research Triangle Park, USA
               type:PostalAddress
            type:Organization
      name:Herbert I. Hurwitz
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:Inderjit Dev
      affiliation:
            name:GlaxoSmithKline
            address:
               name:GlaxoSmithKline, Research Triangle Park, USA
               type:PostalAddress
            type:Organization
      name:Andrew B. Nixon
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:H. Kim Lyerly
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:Timothy Clay
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      name:Michael A. Morse
      affiliation:
            name:Duke University Medical Center
            address:
               name:Duke University Medical Center, Durham, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Duke University Medical Center, Durham, USA
      name:Duke University Medical Center, Durham, USA
      name:GlaxoSmithKline, Research Triangle Park, USA
      name:Hartford Hospital, Hartford, USA
      name:Duke University Medical Center, Durham, USA
      name:GlaxoSmithKline, Research Triangle Park, USA
      name:Duke University Medical Center, Durham, USA
      name:GlaxoSmithKline, Research Triangle Park, USA
      name:Duke University Medical Center, Durham, USA
      name:Duke University Medical Center, Durham, USA
      name:Duke University Medical Center, Durham, USA
      name:Duke University Medical Center, Durham, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(213)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

3.79s.